Introduction {#Sec1}
============

Large for gestational age (LGA) is defined as a birth weight above the 90^th^ percentile for the corresponding gestational age (GA)^[@CR1]^. The maternal factors most closely associated with LGA are maternal obesity, excessive gestational weight gain, maternal gestational diabetes mellitus (GDM), pregestational obesity, and maternal stress^[@CR2]--[@CR9]^. Fetal factors associated with LGA consist primarily of genetic or chromosomal disorders. LGA prevalence is estimated at between 4.6% and 15.3%^[@CR10]^ and is influenced by ethnicity, with higher rates found in children born to African American and non-Hispanic Asian American women in U.S. studies^[@CR11],[@CR12]^.

Excessive fetal growth has negative consequences that extend beyond the neonatal period and these include medium- and long-term neurological, behavioral, and cardiovascular impacts^[@CR13]--[@CR16]^. LGA newborns are also at an increased risk of obesity^[@CR17]--[@CR20]^, metabolic syndrome^[@CR21],[@CR22]^, and insulin resistance^[@CR23]^ in later life. They have also been found to have elevated leptin and fasting insulin and homeostasis model assessment (HOMA) index levels^[@CR24]^ during childhood, in addition to elevated adiponectin levels^[@CR25]^, despite previous reports to the contrary from other studies of insulin states. The risk of obesity in LGA newborns increases with co-occurrence of maternal overweight/obesity or diabetes mellitus^[@CR26]^.

Dysregulation of fatty acid oxidation and subsequent lipotoxicity play an important role in the pathophysiology of obesity-induced insulin resistance^[@CR27],[@CR28]^. Analysis of acylcarnitine profiles by tandem mass spectrometry (MS/MS) in dried-blood spots has been used to investigate fatty acid oxidation alterations in obesity and type 1 and type 2 diabetes mellitus in both human and animal models^[@CR29]--[@CR32]^. A recent systematic review, however, failed to identify a consistent metabolite profile in GDM^[@CR33]^.

The aim of this study was to characterize postnatal plasma acylcarnitine profiles in a cohort of LGA newborns. As a secondary outcome, we analyzed and compared the acylcarnitine fingerprint of LGA infants born to mothers with and without gestational diabetes (LGA-GDM and LGA-noGDM respectively).

Results {#Sec2}
=======

General characteristics of the study population {#Sec3}
-----------------------------------------------

In total, 2514 newborns (1362 males and 1152 females) were included over the 1-year study period. None of them met the exclusion criteria. There were 2302 full-term newborns and 212 preterm newborns, with a medium GA of 39 weeks and the following anthropometric characteristics: mean birth weight, 3225 ± 591 g; mean birth length, 49.05 ± 2.47 cm; and mean head circunference, 34.3 ± 1.66 cm. In the preterm group, the respective measurements were 2127 ± 644 g, 44.03 ± 3.88 cm, and 31.13 ± 2.42 cm. The distribution according to birth weight percentile was 9% for small for GA (SGA) newborns (250/2514), 80.2% for appropriate for GA (AGA) newborns (2018/2514), and 9.7% for LGA newborns (246/2514). All birth measurements were higher in LGA newborns: weight, 4118 ± 234 g; length, 51.95 ± 1.36 cm; and head circumference, 35.97 ± 1.36 cm. Only one preterm newborn included in the study was classified as LGA. A flow diagram of the cohort is shown in Supplementary Figure 1.

The percentage of newborns in the severe LGA group (\>97^th^ percentile) was 3% (75/2514), which is identical to the percentage of newborns in the severe SGA group (\<3^rd^ percentile).There were thus 2364 newborns in the AGA^(3-97)^ group, which contained newborns with a birth weight ≥3^rd^ percentile and ≤97^th^ percentile.

Nine percent (246/2514) of the newborns were born to mothers with a history of GDM; 81.4% of the mothers received dietary treatment and 18.6% required insulin treatment. The breakdown of the LGA group was as follows: 42 LGA-GDM newborns and 204 LGA-noGDM newborns. No significant differences were observed between the mothers in these subgroups for either age or obstetric comorbidities (Supplementary Table [1](#MOESM1){ref-type="media"}).

Acylcarnitine profiles {#Sec4}
----------------------

All acylcarnitine values are expressed as medians and the corresponding 95% confidence interval is given in the tables. Compared with AGA newborns, LGA newborns had higher levels of FC, TC, tAC (*p* \< 0.01), tACm, tACl, and, in particular, tACs (*p* \< 0.01). As shown in Table [1](#Tab1){ref-type="table"}, LGA newborns had the highest tAC/FC ratio (0.795) and the lowest FC/TC ratio (0.557). This was close to the cutoff for neonatal carnitine insufficiency (tAC/FC \> 0.83) and carnitine deficiency (FC/TC \< 0.54), suggesting reduced carnitine storage in this group (SGA, 0.603; AGA, 0.578; and LGA, 0.557) (*p* \< 0.001). Separate analysis of the various acylcarnitines showed remarkably higher levels of C2 and C3 in LGA newborns (*p* \< 0.01), although plasma concentrations for the majority of short- and long-chain acylcarnitines were also higher in the LGA group. The C8/C2 ratio was considerably lower in the LGA group (0.0078 vs. 0.0097 for the AGA group, *p* \< 0.01). The most significant differences between LGA and AGA newborns are summarized in Fig. [1](#Fig1){ref-type="fig"} Table 1Acylcarnitine profiles (µmol/L) according to birth weight based on the 10^th^ and 90^th^ percentiles.SGA (n: 250)AGA (n:2018)LGA (n:246)SGA vs AGAAGA vs LGAMedianRangeMedianRangeMedianRange*P* ^*1*^*95% CIP* ^*2*^*95%CI***FC**33.588.27--80.2427.967.12--100.5628.209.23--80.16**6.8e** ^**−8**^3.73, 6.72*NS*−0.90, 1.75**TC**57.5717.00--118.4449.0120.05--135.8951.2023.26--114.70**2.09e** ^**−7**^5.68, 10.36*NS*0.34, 4.47**tAC**22.168.72--55.9820.497.95--69.4122.3411.83--49.65**0.0003**1.17, 2.88**0.0003**1.11, 2.77**tACs** **C2** **C3** **C3:1** **C4** **C4-OH** **C5** **C5:1** **C5-OH**16.5813.332.760.0010.0020.2760.2510.0280.1536.16--50.204.06--43.780.51--10.060--0.5530--1.6320--0.9110.03--1.0480--0.2630.007--0.4314.2911.502.190.0090.0020.2600.1760.0260.1515.19--62.234.19--58.850.46--9.830--1.750--1.6770--1.7470--1.5780--0.8060--0.88815.8212.832.570.0070.2760.2700.1790.0260.1487.47--41.435.35--36.480.77--8.780--0.4930--1.5260.045--1.9630.018--1.090--0.3020--0.713**4.86e** ^**−7**^ **0.0002** **5.71e** ^**−10**^ *NS* **8.73e** ^**−4**^ *NS* **3.94e** ^**−16**^ *NS* *NS*1.78, 3.21.05, 2.220.41, 0.70−4.0e^**−**5^, 1.5e^**−**5^0.038, 0.078−0.009, 0.0250.062, 0.095−5.9e^**−**5^, 0.003−0.005, 0.011**0.0001** **0.007** **4.42e** ^**−7**^ *NS* *NS* *NS* *NS* *NS* *NS*0.91, 2.230.66, 1.730.27, 0.54−2.9e^**−**5^, 5.2e^**−**5^−0.009, 0.012−0.012, 0.023−0.01, 0.011−0.001, 0.002−0.005, 0.011**tACm** **C6** **C6**--**OH** **C8** **C8:1** **C10** **C10:1** **C10:2** **C5DC** **C4DC** **C12** **C12:1** **C12:20.770**0.0630.0610.1210.2170.1140.1060.0610.080.2800.1370.0830.0270.171--2.610--0.6630--0.2440--0.3610--0.6750--0.4820--0.4140--0.2960--0.3320.04--0.8340--0.6280--0.380--0.153**0.805**0.0400.0500.1100.1800.1280.1010.0520.0670.3320.1520.0930.0260.109--4.980--0.7310--0.4790--2.3940--0.6830--0.9660--0.790--0.4140--0.3950--1.0630--1.7890--0.5020--0.277**0.773**0.5240.0540.1110.2030.1200.0990.0500.0630.3340.1590.0900.0250.202--7.0570--0.3490--0.4030--0.460--0.5810--0.9880--0.7530--0.3950--0.2960.11--1.1060.03--4.3910--0.4610--0.197*NS* *NS* *NS* *NS* *NS* *NS* *NS* *NS* *NS* **1.06e** ^**−9**^ **0.002** *NS* *NS*−0.021, 0.059.4e--6, 0.013−0.002, 0.008−0.002, 0.0140.012, 0.039−0.019, 0.002−0.006, 0.0110.002, 0.0150.003, 0.015−0.071, −0.039−0.029, −0.005−0.021, −0.008−0.001, 0.004*NS* *NS* *NS* *NS* *NS* *NS* *NS* *NS* *NS* *NS* *NS* *NS* *NS*−0.032, 0.038−1.8e^**−**6^, 0.008−0.006, 0.004−0.014, 0.001−0.006, 0.021−0.015, 0.003−0.008, 0.008−0.007, 0.003−0.007, 0.004−0.015, 0.02−0.013, 0.066−0.01, 0.005−0.001, 0.004**tACl** **C14** **C14:1** **C14:2** **C14**--**OH** **C14:1**--**OH** **C16** **C16:1** **C16**--**OH** **C16:1**--**OH** **C18** **C18:1** **C18:2** **C18**--**OH** **C18:1**--**OH** **C18:2**--**OH4.558**0.2770.1320.0810.0350.0412.4540.1620.0370.0561.4681.9380.3500.0330.0960.2141.79--18.080.03--0.7330.03--0.6280--0.7080--0.230--0.2510.87--9.9490--0.4550--0.1690--0.3300.44--6.8570.61--9.2130.07--1.7160--0.1750.004--0.310.02--0.808**5.223**0.2700.1270.0600.0300, 0403.0180.1680.0420.0551.5911.9040.2440.0360.0960.2211.13--19.510.04--1.1380--0.8130--1.1510--0.2590--0.3770.29--12.7870--0.8510--0.3420--0.3460.29--5.7440.3--6.9530.02--1.2630--0.2830--0.5020.002--0.956**5.503**0.2770.1250.0600.0360.0443.2520.1830.0430.0541.6301.9160.2340.0360.0900.2112.22--16.020.09--1.050--0.9760--0.7540--0.1540--0.4071.06--10.7930.01--0.7950--0.2240--0.3160.368--4.9320.738--5.0510.041--1.1050--0.1580.007--0.3950--0.932**4.01e** ^**−7**^ *NS* *NS* **2.5e** ^**−2**^ *NS* *NS* **2.1e** ^**12**^ *NS* *NS* *NS* *NS* *NS* **6.8e** ^**−17**^ *NS* *NS* *NS*--0.837, −0.446−0.01, 0.017−0.004, 0.0130.012, 0.026−0.001, 0.004−0.004, 0.003−0.655, −0.402−0.016, 0.004−0.006, 0.001−0.002, 0.005−0.181, 0.002−0.002, 0.1260.085, 0.12−0.005, 0.004−0.011, 0.004−0.028, 0.001*NS* *NS* *NS* *NS* *NS* *NS* *NS* *NS* *NS* *NS* *NS* *NS* *NS* *NS* *NS* *NS*0.06, 0.476−0.004, 0.024−0.01, 0.006−0.004, 0.008−0.001, 0.005−0.001, 0.0060.09, 0.367−0.004, 0.026−0.003, 0.003−0.004, 0.004−0.044, 0.116−0.026, 0.131−0.02, 0.012−0.002, 0.003−0.009, 0.005−0.031, 0.008**tAC/FC0.657**0.31--1.651**0.728**0.246--2.42**0.795**0.332--1.634**0.005**--0.101, −0.03**0.036**0.019, 0.094**FC/TC0.603**0.37--0.761**0.578**0.292--0.803**0.557**0.38--0.751**0.014**0.011, 0.033**0.0001**−0.031, −0.009p^1^, comparison between SGA and AGA newborns; p^2^, comparison between AGA and LGA newborns; 95% CI, 95% confidence interval; FC, free carnitine; TC, total carnitine; tAC, total acylcarnitines; tACs, total short-chain acylcarnitines; tACm, total medium-chain acylcarnitines; tACl, total long-chain acylcarnitines; SGA, small for gestational age; AGA, appropriate for gestational age; LGA, large for gestational age; NS, p not significant..Figure 1Main differences between large for gestational age (LGA) and appropriate for gestational age (AGA) newborns.

Although severe LGA newborns had higher levels of FC, TC, tAC, tACs, tACm, and tACl, the only significant difference compared with AGA^(3-97)^ newborns were higher levels of C3 (*p* \< 0.05) (Table [2](#Tab2){ref-type="table"} Table 2Acylcarnitine profiles (µmol/L) according to birth weight based on 3^rd^ and 97^th^ percentiles.SGA (n:75)AGA^(3--97)^ (n:2364)LGA (n:75)SGA VS AGAAGA VS LGAMedianRangeMedianRangeMedianRange*P* ^*1*^*95%CIP* ^*2*^*95% CI***FC**35.4314.22--64.0928.317.12--100.5628.2211.58--73.43**0.009**4.01,9.29*NS*−2.29, 2.685**TC**62.3125.14--105.9750.1217.00--135.8952.3325.14--114.70**1.72e** ^**−6**^8.046, 16.168*NS*−2.361, 5.609**tAC**25.2910.92--55.9821.077.95--69.4123.0713.16--49.65**0.0001**2.607, 5.995*NS*0.131, 3.203**tACs** **C2** **C3** **C3:1** **C4** **C4**--**OH** **C5** **C5:1** **C5**--**OH19.41**14.603.670.0020.4430.3370.4890.0320.1758.02--50.205.84--43.781.00--10.060--0.1280.03--1.530--0.9110.128--1.0480--0.1890.007--0.431**14.51**11.672.220.0080.3020.2660.1790.0260.1515.19--62.234.06--58.850.461--9.830--1.750--1.6770--1.9630--1.5780--0.8060--0.888**16.24**12.952.8530.0110.2690.2930.1610.0280.1678.23--41.435.35--36.480.93--5.620--0.1540.10--1.340.045--0.9780.018--1.090--0.1080.032--0.713**9.16e** ^**−9**^ **0.012** **4.61e** ^**−8**^ *NS* **9.66e** ^**−5**^ *NS* **1.30e** ^**−15**^ *NS* *NS*3.472, 6.3571.651, 3.9811.034, 1.732−3.7e^**−**5^, 1.8e^**−**5^0.094, 0.1790.034, 0.0970.239, 0.3496.3e^**−**6^, 0.0110.004, 0.034*NS* *NS* **0**, **015** *NS* *NS* *NS* *NS* *NS* *NS*0.278, 2.7450.171, 2.120.228, 0.76−4.8e^**−**5^, 2.3e^**−**5^−0.049, 0.011−0.019, 0.044−0.023, 0.013−0.003, 0.0060.0002, 0.031**tACm** **C6** **C6**--**OH** **C8** **C8:1** **C10** **C10:1** **C10:2** **C5DC** **C4DC** **C12** **C12:1** **C12:20.688**0.060.0510.1190.1630.1130.0970.0450.080.2210.1250.0730.0250.171--1.4710--0.2680--0.1930--0.3610--0.5940.006--0.3140--0.2510--0.1670--0.3320.04--0.5960--0.3870.006--0.1810--0.114**0.762**0.050.0570.1160.1950.1260.1020.0520.0680.3290.1520.0920.0260.109--7.0570--0.7310--0.4790--2.3940--0.6830--0.9880--0.790--0.4140--0.3950--1.0630--4.3910--0.5020--0.277**0.779**0.0520.0630.1230.2180.1330.1100.0670.070.3250.1570.090.0290.376--3.1080--0.3490--0.4030.026--0.460.039--0.4530--0.2840--0.2520--0.230--0.1780.149--1.1060.047--1.5540--0.4610--0.115*NS* *NS* *NS* *NS* *NS* *NS* *NS* *NS* *NS* **4.86e** ^**−8**^ **4.79e** ^**−6**^ **0.0007** *NS*−0.121, 0.003−6.7e^**−**5^, 0.025−0.013, 0.005−0.008, 0.018−0.043, 0.005−0.03, −0.001−0.02, 0.011−0.015, 0.004−0.001, 0.021−0.12, −0.068−0.062, −0.03−0.031, −0.012−0.003, 0.007*NS* *NS* *NS* *NS* *NS* *NS* *NS* *NS* *NS* *NS* *NS* *NS* *NS*−0.028, 0.087−0.005, 0.013−0.005, 0.013−0.006, 0.02−0.01, 0.034−0.017, 0.013−0.017, 0.0145.1e^**−**6^, 0.022)−0.007, 0.013−0.033, 0.026−0.021, 0.092−0.014, 0.016−2.8e^**−**5^, 0.011**tACl** **C14** **C14:1** **C14:2** **C14**--**OH** **C14:1**--**OH** **C16** **C16:1** **C16**--**OH** **C16:1**--**OH** **C18** **C18:1** **C18:2** **C18**--**OH** **C18:1**--**OH** **C18:2**--**OH4.47**0.2610.1330.0810.030.0382.240.1670.0340.0551.4502.020.3780.0280.0760.2252.239--7.0950.047--0.6580.038--0.460--0.5920--0.1050--0.1320.871--4.3280--0.4410--0.1690--0.1620.583--2.7510.989--3.70.089--0.9910--0.1130.014--0.2740.039--0.797**5.54**0.2720.1280.0610.0350.0422.9960.1690.0420.0551.5801.900.2500.0370.0960.2191.139--19.510.037--1.1380--0.9760--1.1510--0.2590--0.4070.294--12.780--0.8510--0.3420--0.3460.29--6.8570.3--9.2130.022--1.7160--0.2830--0.5020--0.956**5.98**0.2660.1270.0690.0380.0473.300.1760.0440.0551.671.900.2660.0390.1010.2403.045--11.3260.126--0.9770--0.9390--0.7290--0.2590--0.1841.655--6.5290.05--0.7950--0.1670.009--0.3160.518--3.0380.987--3.8090.041--0.5670--0.1580.019--0.2240.027--0.831**2.86e** ^**−8**^ *NS* *NS* *NS* *NS* *NS* **9.39e** ^**−12**^ *NS* *NS* *NS* *NS* *NS* **1.31e** ^**−6**^ **0.016** *NS* *NS*−1.13, −0.482−0.02, 0.0190.01, 0.020.008, 0.03−0.008, 0.002−0.01, −0.001−0.95, −0.524−0.025, 0.011−0.01, −0.002−0.005, 0.007−0.177, 0.033−0.073, 0.210.093, 0.16−0.013, −0.004−0.02, −4.3e^**−**4^−0.04, 0.018*NS* *NS* *NS* *NS* *NS* *NS* *NS* *NS* *NS* *NS* *NS* *NS* *NS* *NS* *NS* *NS*−0.046, 0.648−0.022, 0.028−0.015, 0.015−0.007, 0.017−0.004, 0.0070.001, 0.0130.007, 0.459−0.007, 0.031−0.004, 0.006−0.006, 0.006−0.078, 0.148−0.054, 0.225−0.023, 0.042−0.001, 0.008−0.005, 0.02−0.031, 0.039**tAC/FC0.693**0.314--1.58**0.724**0.246--2.42**0.776**0.431--1.634*NS*−0.096, 0.042*NS*−0.014, 0.112**FC/TC0.591**0.388--0.761**0.580**0.292--0.803**0.563**0.38--0.699*NS*−0.008, 0.032*NS*−0.038, 0.001p^1^, comparison between severe SGA and AGA^(3--97)^ groups; p^2^, comparison between AGA^(3--97)^ and severe LGA groups; 95% CI, 95% confidence interval; FC, free carnitine; TC, total carnitine; tAC, total acylcarnitines; tACs, total short-chain acylcarnitines; tACm, total medium-chain acylcarnitines; tACl, total long-chain acylcarnitines; SGA, small for gestational age; AGA, appropriate for gestational age; LGA, large for gestational age; NS, p not significant.). In addition, no increase in carnitine deficiency or insufficiency markers was observed in this group.

The comparison between LGA-GDM and LGA-noGDM newborns revealed that a history of gestational diabetes was associated with higher levels of FC, TC, and short-chain acylcarnitines, including propionylcarnitine (LGA-GDM: 3.33 µmol/L; LGA-noGDM: 2.69 µmol/L), and lower levels of medium- and long-chain acylcarnitines, although the differences were not significant (Table [3](#Tab3){ref-type="table"}). Analysis of the individual acylcarnitines revealed no remarkable differences between the two subgroups.Table 3Acylcarnitine pattern (µmol/L) in LGA newborns according to maternal history of gestational diabetes.LGA-noGDM (n:204)LGA-GDM (n:42)*P*95% CIMedianRangeMedianRangeFC27.939.235--80.16430.1719.11--58.364*NS*−5.81, 0.93TC50.4823.265--114.70354.1737.47--103.696*NS*−9.16, 1.13tAC22.2911.831--49.65323.3717.241--45.332*NS*−3.88, 0.64tACs15.657.474--41.43817.1111.224--36.76*NS*−3.69, −0.05tACm0.770.202--7.0570.8070.483--1.557*NS*−0.10, 0.06tACl5,562.228--16.0235.0812.879--9.113*NS*−0.16, 0.88tAC/FC0.8090.332--1.6340.7770.505--1.624*NS*−0.09, 0.11FC/TC0.5530.38--0.7510.5630.381--0.664*NS*−0.03, 0.02GDM, gestational diabetes mellitus; FC, free carnitine; TC, total carnitine; tAC, total acylcarnitines; tACs, total short-chain acylcarnitines; tACm, total medium-chain acylcarnitines; tACl, total long-chain acylcarnitines; SGA, small for gestational age; AGA, appropriate for gestational age; LGA, large for gestational age; NS, p not significant; 95% CI, 95% confidence interval.

Discussion {#Sec5}
==========

Disturbances in fetal nutrition, such as intrauterine growth restriction (IUGR) and macrosomia, can impact health during adolescence and adulthood^[@CR13]--[@CR16],[@CR34]^ and are risk factors for later overweight^[@CR17]--[@CR20],[@CR35],[@CR36]^. Animal studies have shown that fetal overnutrition results in increased adiposity in newborns, leading to insulin resistance similar to that seen in cases of postnatal overnutrition^[@CR37]^. Given the high worldwide prevalence of child obesity and overweight^[@CR38]^, improved knowledge of metabolic homeostasis in higher-risk subgroups, such as LGA newborns, is essential for identifying possible treatment targets.

Recent investigations have identified abnormalities in the metabolic profiles of obese adults and children, such as increased plasma concentrations of branched-chain amino acids (BCAAs) (valine, leucine, and isoleucine), BCAA metabolism byproducts (e.g. alanine, glutamate/glutamine), C3 and C5 acylcarnitines, and aromatic amino acids (phenylalanine and tyrosine)^[@CR29],[@CR39]--[@CR44]^. The increase in BCAA and short-chain acylcarnitine concentrations is linked to elevated protein intake^[@CR45]^, and levels are positively correlated with adiposity^[@CR46],[@CR47]^ and strongly associated with IR^[@CR29],[@CR32],[@CR44],[@CR48]^. The metabolic environment in LGA is less well-known. Higher levels of adipokines^[@CR49]^, BCAAs, and other metabolites, such as alanine, glutamine, threonine, citric acid, glycerol, and glucose, have been detected in cord-blood samples of LGA newborns^[@CR50]^, and similar findings have been reported for myo-inositol levels in urine samples^[@CR51]^.

Ours is the first study to characterize acylcarnitine profiles in LGA newborns. In line with the results of obesity studies in children^[@CR41],[@CR43]^ and adults^[@CR29],[@CR31]^, our data show that LGA newborns have increased postnatal levels of C3, a product of mitochondrial BCAA catabolism, and in particular of isoleucine and valine catabolism^[@CR29]^. BCAAs act as signaling molecules of nutritional status^[@CR52]^. Increased concentrations in obese and insulin-resistant humans may be caused by down-regulation of BCAA oxidation enzymes in adipose tissue^[@CR53],[@CR54]^, as has been observed in animal models with genetic or diet-induced obesity^[@CR55]^. Propionylcarnitine is a carnitine conjugate of propionyl-CoA, which has been identified as a potential substrate for odd-chain fatty acid synthesis^[@CR56]^. Moreover, C3 and C5 levels are promising biomarkers for discriminating metabolic wellness in obese individuals^[@CR57]^, as higher levels have been observed in metabolically unhealthy individuals, independently of body mass index^[@CR58]^. Consistent with these observations, the LGA newborns in our study had higher C3 (*p* \< 0.001) and C5 levels than AGA newborns, and the concentrations of C3 were even higher than those observed in obese children^[@CR41],[@CR43]^ and adults^[@CR29]^. This could reflect an unhealthy metabolic status in LGA newborns with potential complications in later life. The LGA group also had higher C2 plasma levels, and these were particularly evident in severe LGA newborns. C2 may play a role in insulin resistance through its interaction with acetyl-CoA via carnitine acetyl-CoA transferase. This enzyme seems to act as a positive regulator of total body glucose tolerance and muscle activity of pyruvate dehydrogenase^[@CR59]^. C2 levels are increased in prediabetic states^[@CR60]^, diabetes mellitus^[@CR30],[@CR32],[@CR60]^, and metabolic syndrome^[@CR32]^, and are significantly and positively correlated with HbA~1c~ levels^[@CR30]^. Interestingly, the levels in the LGA group were higher than those reported for diabetic adult patients^[@CR30],[@CR32],[@CR60]^.

One of the most notable differences between LGA and AGA newborns in our study was the significantly higher tACs levels in the LGA group (*p* \< 0.0001). This observation is consistent with reports of increased tACs in obesity, impaired glucose tolerance, and diabetes mellitus^[@CR61]^.

The acylcarnitine pattern of increased tAC, tACs, C2, and C3 levels was more evident in the SGA group, supporting previous observations in animal models^[@CR62]^ and neonatal studies^[@CR63]^, and suggesting an impaired fatty acid metabolism in both fetal growth disorders.

In agreement with the profile described for overweight adults^[@CR29]^ and children^[@CR64]^, LGA newborns also showed higher (though not significantly so) concentrations of medium- and long-chain acylcarnitines than AGA newborns.

A strong correlation was recently demonstrated between carnitine and body composition^[@CR65]^. Although we observed slightly higher plasma concentrations of free carnitine in LGA newborns, our data also showed a greater tendency towards carnitine deficiency (*p* \< 0.05) and insufficiency (*p* \< 0.001) in this group. Increases in tAC/FC ratio precede a decrease in total plasma carnitine and indicate low tissue bioavailability of FC^[@CR66]^. The higher FC levels in LGA contrast with the carnitine depletion reported for diet-induced obesity^[@CR67]^. Nevertheless, metabolomic studies of obesity have also shown higher levels of carnitine in obese children^[@CR43]^. Carnitine insufficiency in our cohort appears to be unrelated to antenatal exposure to GDM. This is relevant given the proposed causative role of carnitine insufficiency in mitochondrial dysfunction and obesity-related impairments in glucose tolerance^[@CR68]^. It is also consistent with reports that document that GDM in pregnant women does not negatively affect the efficiency of the carnitine system^[@CR69]^. We did not find any postnatal differences between acylcarnitine profiles in LGA-GDM and LGA-noGDM newborns in our study, although the former had higher concentrations of FC, TC, tAC and tACs. In line with this observation, higher FC and TC levels have been reported in pregnant women with GDM versus healthy pregnant women at 30--33 weeks of gestation^[@CR69]^. We do not consider that the absence of significant differences between the LGA-GMD and LGA-no GDM groups is due to sample size, as the minimum detectable effect sizes for the samples used in each comparison (with 5% significance and 80% statistical power) were 0.2 for AGA vs LGA and AGA vs SGA (Table [1](#Tab1){ref-type="table"}), 0.25 for SGA vs LGA (Table [1](#Tab1){ref-type="table"}), 0.33 for AGA vs LGA (Table [2](#Tab2){ref-type="table"}), and 0.48 for LGA-noGMD vs LGA-GMD (Table [3](#Tab3){ref-type="table"}). This means that, even in the worst-case scenario (Table [3](#Tab3){ref-type="table"}), we are able to detect true between-group differences of higher than 50% of the SD, which are considered medium effect sizes^[@CR70]^.

Our findings describe a postnatal acylcarnitine profile in LGA newborns that is characteristic of obesity and associated with the development of insulin resistance and prediabetic states, supporting the view that early imbalance in metabolic homeostasis in LGA newborns could contribute to deleterious effects in the long term. Identification of this profile, linked to an unhealthy metabolic phenotype, in the postnatal period could help to establish early dietary intervention and follow-up to reduce the risk of overweight and metabolic syndrome in later life.

Patients and Methods {#Sec6}
====================

Study design {#Sec7}
------------

The acylcarnitine profiles of LGA newborns were determined in a 1-year observational study approved by the Research Ethics Committee of Galicia, Spain (registry number 2015/315). The processing of clinical data for research purposes at the beginning of the study and the study protocol complied with the principles of the Helsinki Declaration of 1964, as revised in October 2013 in Fortaleza, Brazil.

Patients {#Sec8}
--------

This study was conducted at Hospital Clínico Universitario de Santiago de Compostela, a tertiary hospital in north-west Spain. All newborns born in or referred to our hospital during the first 48 hours of life over the period of 1 year (2015) were included in the study. Informed consent was obtained from parents or legal guardians. Infants with an established diagnosis of an inborn error of metabolism known to alter acylcarnitine profiles (primary systemic carnitine deficiency, mitochondrial fatty acid ß-oxidation defects, ß-ketothiolase deficiency, propionic, methylmalonic or isovaleric acidemia, 3-methylcrotonyl-CoA carboxylase deficiency, 3-hydroxy-3-methylglutaryl-CoA lyase deficiency, or 3-methylglutaconic aciduria) were excluded from the analysis. The following variables were recorded at birth: sex, gestational age, weight (g), length (cm), head circumference (cm), history of GDM, and treatments received (dietary and/or insulin treatment).

Newborns were classified into the following groups according to their birth weight: AGA (≥10^th^ percentile and ≤90^th^ percentile of birth weight for GA), SGA (\<10^th^ percentile of birth weight for GA), and LGA (\>90^th^ percentile of birth weight for GA). For additional analyses we also classified newborns with a birth weight greater than the 97^th^ percentile for GA into a severe LGA group.

Birth weight percentiles and z-scores for GA were calculated using the online nutritional assessment tool of the Spanish Society of Gastroenterology, Hepatology and Nutrition ([www.gastroinf.es](http://www.gastroinf.es)), which is based on Spanish neonatal growth curves^[@CR71]^.

GDM was defined according to the criteria established in the 2016 Guidelines of the American Diabetes Association^[@CR72]^ using the two-step diagnostic strategy: 1) if plasma glucose is ≥140 mg/dL (7.8 mmol/L) in the 1-hour glucose loading-test, pregnant women must 2) undergo a glucose tolerance test (administration of 100 g of glucose after 8 hours of fasting with subsequent sequential blood sampling). Diagnosis is confirmed when two or more of the following glucose criteria are fulfilled: fasting, ≥105 mg/dL (5.8 mmol/L); 1 hour, ≥190 mg/dL (10.6 mmol/L); 2 hours, ≥165 mg/dL (9.2 mmol/L); and 3 hours, ≥145 mg/dL (8.0 mmol/L).

Based on the corresponding obstetric history of gestational diabetes, LGA newborns were sub-classified as LGA-GDM (co-occurrence of gestational diabetes) or LGA-noGDM (absence of GDM).

Tandem mass spectrometry and study parameters {#Sec9}
---------------------------------------------

Analyses of free carnitine and acylcarnitines were performed on a tandem mass spectrometer coupled to a triple quadrupole analyzer (ESI-MS/MS API 2000; Applied Biosystems Sciex, Toronto, Canada) following an established methodology^[@CR73]^.

The plates were prepared using the following protocol. The paper blood sample disks and patterns were cut using a BSD 700 automatic drill (BSD tech., Brisbane, Australia) and hand drills followed by microplate placement and addition to each well of methanol. Acylcarnitines were purified with methanol and stable isotope-labeled patterns were used to determine their respective concentrations. The acylcarnitines were then extracted by vortex shaking for 25 minutes. Subsequently, all the methanol was transferred to another plate to distil the blood disks and then evaporated in a gas extractor. The acylcarnitines were derivatized with butanol to their butyl-esters in an acid medium to increase the selectivity of the technique. This was done with the addition of 3N HCl in n-butanol followed by heating at 65 ± 5 °C for 20 minutes and cooling for 5 minutes in a freezer. Excess butanol was evaporated to dryness and once the evaporated plates were at room temperature, a new solution was prepared with 100 μL of the mobile phase of the chromatograph (acetonitrile: water, 1:1). The plates were then covered with foil, vortexed for 5 minutes, and finally analyzed (precursor m/z 120--280 amu).

The reagents were prepared using water purified with a Milli-Q system (Millipore) and the mobile phase was composed of acetonitrile (LiCrosolv Merck, ref. 00030) and formic acid 0.005% (Merck, ref.02264).

A comprehensive analysis of acylcarnitine profiles was conducted by MS/MS using dried~~-~~blood spots collected on the third day of life for expanded newborn screening. We analyzed: *short-chain acylcarnitines*: acetyl- (C2), propionyl- (C3), propenyl- (C3:1), C4-, 3-OH-butyryl- (C4-OH), C5- and tiglyl-carnitine (C5:1); *medium-chain acylcarnitines*: C6-, 3-hydroxy-hexanoyl- (C6-OH), C8-, octenoyl- (C8:1), methylmalonyl- (C4DC), C10-, decenoyl- (C10:1), decadienoyl- (C10:2), C12- and dodecenoyl-carnitine (C12:1); and *long-chain acylcarnitines*: C14-, myristoleyl- (C14:1), hydroxymyristoyl- (C14-OH), C16-, hexadecenoyl- (C16:1), 3-hydroxi-hexadecanoyl- (C16-OH), 3-hydroxypalmitoleylc- (C16:1-OH), C18-, oleyl- (C18:1), linoleyl- (C18:2), hydroxyoleyl- (C18:1-OH) and 3-hydroxy-linoleyl-carnitine (C18:2-OH). It should be noted that the analytical method employed does not allow for the differentiation of isobaric acylcarnitines. The following parameters were also assessed: total short-chain acylcarnitines (tACs), total medium-chain acylcarnitines (tACm), total long-chain (tACl) acylcarnitines (the sum of short-, medium-, and long-chain acylcarnitines, respectively), total acylcarnitines (tAC) (the sum of all acylcarnitines studied); total carnitine (TC), defined as the sum of free carnitine (FC) and total acylcarnitines (tAC), FC/TC ratio (values \<0.54 in neonates are suggestive of carnitine deficiency), and tAC/FC ratio (values \>0.83 in newborns are indicative of carnitine insufficiency)^[@CR74]^. We also evaluated three acylcarnitine ratios typically included in neonatal screening: C8/C2, C8/C10, and FC/C16.

Statistical analyses {#Sec10}
--------------------

Data were analyzed using the R statistical package (version 3.2.1; R Project for Statistical Computing). Sample normality was assessed using the Kolmogorov-Smirnov test. ANOVA was used to compare normally distributed data, and the Kruskal--Wallis test was used to compare non-normally distributed data. Qualitative variables were compared using Fisher's exact test. Normal samples with unknown variance were compared using Student's t-test, while non-normally distributed data were compared using the Wilcoxon rank test. Finally, the *p*-values obtained were adjusted using Bonferroni correction. Only adjusted *p*-values \< 0.05 were considered statistically significant.
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